A detailed history of Sectoral Asset Management Inc transactions in Bio N Tech Se stock. As of the latest transaction made, Sectoral Asset Management Inc holds 13,155 shares of BNTX stock, worth $1.5 Million. This represents 1.3% of its overall portfolio holdings.

Number of Shares
13,155
Previous 27,265 51.75%
Holding current value
$1.5 Million
Previous $2.19 Million 28.71%
% of portfolio
1.3%
Previous 1.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$78.36 - $124.66 $1.11 Million - $1.76 Million
-14,110 Reduced 51.75%
13,155 $1.56 Million
Q2 2024

Aug 13, 2024

BUY
$80.36 - $102.87 $1.91 Million - $2.44 Million
23,740 Added 673.48%
27,265 $2.19 Million
Q1 2024

May 14, 2024

SELL
$88.96 - $112.35 $17,792 - $22,470
-200 Reduced 5.37%
3,525 $325,000
Q4 2023

Feb 14, 2024

BUY
$90.91 - $112.75 $25,454 - $31,570
280 Added 8.13%
3,725 $393,000
Q3 2023

Nov 14, 2023

BUY
$98.5 - $125.08 $11,426 - $14,509
116 Added 3.48%
3,445 $374,000
Q2 2023

Aug 11, 2023

BUY
$102.58 - $129.66 $64,522 - $81,556
629 Added 23.3%
3,329 $359,000
Q3 2022

Nov 10, 2022

BUY
$127.65 - $183.11 $63,825 - $91,555
500 Added 22.73%
2,700 $364,000
Q2 2022

Aug 15, 2022

SELL
$123.25 - $186.24 $51,765 - $78,220
-420 Reduced 16.03%
2,200 $328,000
Q1 2022

May 10, 2022

SELL
$126.25 - $231.85 $42,293 - $77,669
-335 Reduced 11.34%
2,620 $447,000
Q4 2021

Feb 11, 2022

BUY
$216.64 - $362.52 $401,867 - $672,474
1,855 Added 168.64%
2,955 $762,000
Q3 2021

Nov 15, 2021

BUY
$205.93 - $447.23 $226,523 - $491,953
1,100 New
1,100 $300,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.7B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Sectoral Asset Management Inc Portfolio

Follow Sectoral Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sectoral Asset Management Inc with notifications on news.